Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Most breast cancer patients could avoid chemo with use of genetic testing

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 03.06.18
Views: 856
Rating:

Dr Joseph Sparano - Albert Einstein Cancer Center, New York, USA

Dr Sparano speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about data from the TAILORx trial.

The results show that 70% of women with early HR / HER2- breast cancer could be spared chemotherapy.

For more on these results, watch Dr Sparano present the data in a press conference and read our news coverage here.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

ONJ e-learning


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence